MaxCyte, Inc. (NASDAQ:MXCT) Shares Acquired by Valmark Advisers Inc.

Valmark Advisers Inc. raised its holdings in MaxCyte, Inc. (NASDAQ:MXCT) by 6.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 123,203 shares of the company’s stock after acquiring an additional 7,549 shares during the quarter. Valmark Advisers Inc. owned 0.12% of MaxCyte worth $336,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Tower Research Capital LLC TRC lifted its holdings in MaxCyte by 123.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,564 shares of the company’s stock valued at $31,000 after acquiring an additional 4,173 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in MaxCyte in the 4th quarter valued at about $56,000. Kwmg LLC acquired a new stake in MaxCyte in the 1st quarter valued at about $40,000. Prudential Financial Inc. acquired a new stake in MaxCyte in the 4th quarter valued at about $65,000. Finally, Catalyst Funds Management Pty Ltd acquired a new stake in MaxCyte in the 4th quarter valued at about $74,000. 68.81% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Stifel Nicolaus cut their price target on shares of MaxCyte from $11.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday, March 12th. Wall Street Zen raised shares of MaxCyte from a “sell” rating to a “hold” rating in a report on Sunday, June 8th. Finally, BTIG Research set a $6.00 price objective on MaxCyte and gave the stock a “buy” rating in a report on Wednesday, March 12th.

MaxCyte Trading Up 0.9%

NASDAQ MXCT opened at $2.23 on Thursday. The stock’s 50-day moving average price is $2.39 and its two-hundred day moving average price is $3.32. The company has a market cap of $237.32 million, a PE ratio of -5.57 and a beta of 1.27. MaxCyte, Inc. has a 1 year low of $2.00 and a 1 year high of $5.20.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.10). The firm had revenue of $10.39 million for the quarter, compared to the consensus estimate of $9.05 million. MaxCyte had a negative return on equity of 19.90% and a negative net margin of 110.92%. Research analysts forecast that MaxCyte, Inc. will post -0.42 EPS for the current fiscal year.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.